CD274 and small cell lung carcinoma: The anti–programmed death ligand‐1 (PD‐L1) antibody, atezolizumab, in combination with etoposide and carboplatin (E/P) was approved by the U.S. Food and Drug Administration (FDA) in 2019 for the first‐line treatment of patients with ES‐SCLC.